HALO Halozyme Therapeutics
- 45.700
- -0.060-0.13%
- 46.150
- +0.450+0.98%
Halozyme Therapeutics News
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO Vs. FOLD: Which Stock Should Value Investors Buy Now?
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
Evotec Plunges Amid Report It's Against Halozyme Therapeutics Takeover
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $62
Halozyme Says EUR2 Billion Takeover of Evotech Would Create Leader in Drug Discovery
Express News | Halozyme Therapeutics Inc - All-Cash Transaction Funded by Cash and New Debt
Express News | Halozyme Provides Update on Non-Binding Proposal to Combine With Evotec
Halozyme Therapeutics (HALO.US) plans to acquire Evotech (EVO.US) for 2.1 billion dollars in cash.
Halozyme Therapeutics financed the acquisition of German company Evotec for 2 billion euros (equivalent to 2.1 billion dollars) in cash.
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Evotec Shares Are Trading Higher After Halozyme Therapeutics Confirmed a Cobmination Offer.
Sector Update: Health Care Stocks Retreat Friday Afternoon
Halozyme Therapeutics Sinks After Confirming Evotec Buyout Offer
Halozyme Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since January 2016 -- Data Talk
Here's Why Halozyme Therapeutics (HALO) Is a Strong Momentum Stock
Evotec Shares Surge on $2.11 Billion Buyout Offer
J.P. Morgan Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Announces Target Price $54
Halozyme's Financing of Potential Evotec Deal Remains a Question -- Market Talk
Analysis
Price Target
No Data
No Data